Product Information
Registration Status: ActiveTHERACAP 131TM CAPSULE is approved to be sold in Singapore with effective from 2002-11-05. It is marketed by GE HEALTHCARE PTE LTD, with the registration number of SIN11923P.
This product contains Sodium Iodide 37 MBq to 5.55 GBq in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by GE HEALTHCARE BUCHLER GMBH & CO KG in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine. Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.
Indication
Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [L2065].
Pharmacokinetics
- Absorption
- Iodide salts are readily absorbed in the gastrointestinal tract [L2061].
- Distribution
- Iodides are distributed widely throughout extracellular fluid of thyroid gland [L2061].
- Metabolism
- Elimination
Toxicity
Acute oral LD50 is 4340 mg/kg in rat and 1000 mg/kg in mouse [MSDS]. Chronic iodide overdoses may result in iodism, which is commonly characterized by salivation, coryza, sneezing, conjunctivitis, headache, fever, laryngitis, bronchitis, stomatitis, parotitis and oedema of the glottis [L2061]. Up to 10g of sodium iodide has been administered intravenously without any signs of toxicity [L2061].
Active Ingredient/Synonyms
Sodium iodide | Sodium iodide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.